Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with unmet medical need. Its lead product candidate, Deramiocel, is an allogeneic cell therapy comprised of cardiosphere-derived cells (CDCs) designed to address cardiac and skeletal muscle complications associated with DMD. The company’s Biologics License Application for Deramiocel is under review by the U.S. Food and Drug Administration. Capricor also operates the StealthX exosome platform, which focuses on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics. The company collaborates with research institutions including the National Institutes of Health, Johns Hopkins University, and Cedars-Sinai Medical Center. Nippon Shinyaku serves as the exclusive distributor for DMD in the United States and Japan. Capricor was founded in 2005 and became a public company in 2013 following a merger with Nile Therapeutics.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage capricor.com
Sector Healthcare IR page capricor.com/investors
Tags
cell therapy, exosome technology, duchenne muscular dystrophy, cardiac muscle disease, skeletal muscle disease, vaccinology, drug delivery, rare diseases, allogeneic cells, cardiosphere-derived cells, Deramiocel, StealthX, Nippon Shinyaku, Nile Therapeutics, Capricor Inc.
Press page capricor.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 550.576M
Market cap (USD) $ 550.576M
P/E -3.59
PEG —
P/BV 2.62
P/S 24.72
P/OCF -4.59
P/FCF -4.15
Dividend yield —
Turnover / mcap —
Returns  
ROE -46.6%
ROI -325.6%
ROIC -251.4%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 47
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 0 22.27M 25.178M 2.551M 244.898K 310.25K 1.005M 1.671M 2.666M 3.999M 5.518M 4.787M — 195.5K 1.355M — — —
Net profit -105.044M -40.467M -22.288M -29.02M -20.023M -13.657M -7.642M -15.191M 2.431M -18.807M -12.857M -6.217M -8.892M -1.893M -4.885M -6.031M — —
Free cash flow -72.716M -41.163M -26.908M 2.916M -18.006M -10.602M -6.822M -14.179M -14.263M -15.994M -10.947M 772.131K -6.2M -2.187M -4.651M -4.32M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 28.86 13.8 4.89 3.86 2.93 3.43 1.28 0.4 1.58 2.66 3.07 — — — — — — —
Price performance 12m 1.09 1.82 0.27 0.32 -0.15 1.68 2.16 -0.74 -0.41 -0.13 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — — 0.00 2.87M 2.56M 2.24M 1.45M 14.5M
Cash and deposits (USD) 3.2M 6.14M 4.26M 3.9M 32.7M 34.9M 9.6M 14.7M 11.3M 288M
Intangible assets (USD) 142,253 93,048 49,772 6,495 2,165 0.00 — — — —
Right-of-use assets (USD) — — — — 0.00 2.82M 2.35M 2.05M 1.31M 13.5M
Cash flow detail
Operating cash flow (USD) -15.8M -14.2M -13.9M -6.82M -10.1M -16.8M 4.92M -25.6M -40M -69.8M
Purchases of property, plant and equipment (USD) -191,970 -32,185 -316,486 0.00 -547,601 -1.2M -2M -1.31M -1.17M -2.9M
Share buybacks (cash effect) (USD) — — 0.00 -193 0.00 — — — — —
Interest paid (cash effect) (USD) -1,343 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income taxes paid (cash effect) (USD) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,600
Share-based compensation (USD) 1.96M 1.71M 1.73M 700,984 1.95M 2.97M 4.46M 7.39M 9.77M 17.2M
Free cash flow (OCF - PPE - intangibles) (USD) -16M -14.3M -14.2M -6.82M -10.6M -18M 2.92M -26.9M -41.2M -72.7M
Income detail
Research and development expense (USD) 16M 10.8M 12.1M 5.14M 8.46M 13.6M 21.8M 36.4M 50M 84.5M
↳ 5y CAGR +31.1% +60.1% +18.3% -8.0% -9.3% -3.3% +15.2% +24.7% +57.6% +58.4%
Total comprehensive income (USD) -18.8M 2.44M -15.2M -7.65M -13.7M -20M -28.9M -22.2M -39.7M -106M
Comprehensive income to owners (USD) -18.8M 2.44M -15.2M -7.65M -13.7M -20M -28.9M -22.2M -39.7M -106M
Reported Mar 16, 2017 Mar 22, 2018 Mar 27, 2020 Mar 27, 2020 Mar 11, 2022 Mar 11, 2022 Mar 17, 2023 Mar 11, 2024 Mar 26, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

● Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026

● Major BLA amendment added two-year open-label extension (OLE) HOPE-3 data and proposed a refined indication focused on upper limb impairment in patients > 9 years old

● Two-year HOPE-3 OLE data presented at the World Muscle Society (WMS) Congress: 76% slower upper limb decline after patients switched from placebo to Deramiocel

● HOPE-3 cardiac results received the American Heart Association (AHA) Outstanding Research Award in Pediatric Cardiology

● Cash, cash equivalents, restricted cash and marketable securities of approximately $199 million as of September 30, 2026

● Conference call and webcast today at 4:30 p.m. ET

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

November 03, 2026 9:00 am EST Download as PDF

– Company to Host Conference Call on November 10, 2026, at 4:30 p.m. ET –

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics  (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.

Title: Capricor Therapeutics Third Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast
Date: Tuesday, November 10, 2026
Time: 4:30 p.m. ET
Call Details: Toll-Free: 1-800-717-1738
International: 1-646-307-1865
Conference ID: 13662
Participants may dial in using the numbers above and ask to be joined to the call, or use the Call me™ link for instant telephone access to the event.
Webcast: Click here

A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com .

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook , Instagram  and X .

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

Nov 10, 2026 4:30 pm EST

Conference Call Details:
Toll-Free: 1-800-717-1738
International: 1-646-307-1865
Conference ID: 13662

Participants may dial in using the numbers above and ask to be joined to the call, or use the Call me™   link for instant telephone access to the event.

Webcast

Audio

©2026 Capricor Therapeutics, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap Manage Cookie Preferences

Prompts

Capricor Therapeutics, Inc. (ticker CAPR), listed in United States.

Company History

Date Change Detail
Oct 7, 2013 Renamed NILE THERAPEUTICS, INC. → CAPRICOR THERAPEUTICS, INC.
Sep 21, 2007 Renamed SMI PRODUCTS INC → NILE THERAPEUTICS, INC.

ETFs Holding Capricor Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.34% 125,328 $ 1.242M Aug 31, 2026
FSEG 0.07% 168 $ 4,045.44 Jun 30, 2026
RESM 0.04% 61 $ 1,468.88 Jun 30, 2026
WCEO 0.03% 860 $ 3,311.00 Jul 31, 2026
FESM 0.01% 16,452 $ 396.164K Jun 30, 2026
MSSM 0.00% 1,275 $ 12.635K Aug 31, 2026